Nexus Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Nexus Pharmaceuticals's estimated annual revenue is currently $40.6M per year.
- Nexus Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Nexus Pharmaceuticals has 202 Employees.
- Nexus Pharmaceuticals grew their employee count by 21% last year.
Nexus Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $10.7M | 53 | 56% | N/A | N/A |
#2 | $70.4M | 350 | 1% | N/A | N/A |
#3 | $23.9M | 119 | 13% | $35M | N/A |
#4 | $12.7M | 63 | -3% | N/A | N/A |
#5 | $5.4M | 27 | -25% | N/A | N/A |
#6 | $9.2M | 46 | -2% | N/A | N/A |
#7 | $35.3M | 374 | 6% | $289.7M | N/A |
#8 | $7.2M | 36 | -23% | N/A | N/A |
#9 | $13.9M | 69 | 8% | N/A | N/A |
#10 | $186.3M | 927 | 19% | N/A | N/A |
What Is Nexus Pharmaceuticals?
Nexus Pharmaceuticals, Inc. is a niche Generic pharmaceutical company located in 175 E Hawthorn Pkwy, Vernon Hills, Illinois, United States.
keywords:N/AN/A
Total Funding
202
Number of Employees
$40.6M
Revenue (est)
21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nexus Pharmaceuticals News
Trisenox (arsenic trioxide) Market Size 2022 Segments, Competitors Strategy, Regional Analysis, Key Players |Teva, Fresenius Kabi, Nexus Pharmaceuticals,.
... Marathon Pharmaceuticals, Bausch Health Companies, Pfizer, Sanofi, Sterling-Winthrop, Cipla USA, Amneal Biosciences, Nexus Pharmaceuticals .
Nexus Pharmaceuticals, a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-...
During a special meeting, the board voted 5-0 to rezone two wetland areas to the west and south of the property for the Nexus Pharmaceuticals ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $32.5M | 204 | 7% | N/A |
#2 | $56.2M | 224 | 5% | N/A |
#3 | $68.5M | 248 | -2% | N/A |
#4 | $78.1M | 263 | 0% | N/A |
#5 | $65.2M | 289 | -8% | N/A |